Publications

Original research

1. Papadopoulos, C.; Mimidis, K.; Tentes, I.; Anagnostopoulos, K. Erythrocyte TLR9 is upregulated in metabolic associated fatty liver disease, and is linked to an inflammatory immunometabolic signature.biorxiv. https://doi.org/10.1101/2024.01.23.576889 
2. Papadopoulos, C; Voulgaris, A; Tentes, I; Archontogeorgis, K; Nena, E; Steiropoulos, P; Levels of lipids in erythrocyte membrane and lipoproteins in plasma in patients with obstructive sleep apnea. ERJ Open Research, 2023, s11
3. Papadopoulos, C.; Spourita, E.; Mimidis, K.; Kolios, G.; Tentes, L.; Anagnostopoulos, K. Nonalcoholic Fatty Liver Disease Patients Exhibit Reduced CD47 and Increased Sphingosine, Cholesterol, and Monocyte Chemoattractant Protein-1 Levels in the Erythrocyte Membranes. Metab. Syndr. Relat. Disord. 2022, 20, 377–383.
4. Papadopoulos, C.; Mimidis, K.; Papazoglou, D.; Kolios, G.; Tentes, I.; Anagnostopoulos, K. Red Blood Cell-Conditioned Media from Non-Alcoholic Fatty Liver Disease Patients Contain Increased MCP1 and Induce TNF-α Release. Rep. Biochem. Mol. Biol. 2022, 11, 54–62.
5. Papadopoulos, C.; Mimidis, K.; Tentes, I.; Tente, T.; Anagnostopoulos, K. Validation and application of a protocol for the extraction and quantitative analysis of sphingomyelin in erythrocyte membranes of patients with non-alcoholic fatty liver disease. JPC-J. Planar Chromatogr. 2021, 34, 411–418.
6. Papadopoulos, C.; Panopoulou, M.; Mylopoulou, T.; Mimidis, K.; Tentes, I.; Anagnostopoulos, K. Cholesterol and Phospholipid Distribution Pattern in the Erythrocyte Membrane of Patients with Hepatitis C and Severe Fibrosis, before and after Treatment with Direct Antiviral Agents: A pilot Study. Maedica, 2020, 15(2), 162–168.

Reviews

1. Papadopoulos C. Molecular and Immunometabolic landscape of erythrophagocytosis-induced ferroptosis. Cardiovasc. Hematol. Disord. Drug Targets 2025, accepted
2. Papadopoulos C. The molecular determinants of erythrocyte removal impact the development of metabolic dysfunction-associated steatohepatitis. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2024, accepted
   
3. Papadopoulos, C.; Anagnostopoulos, K.; Tsiptsios, D.; Karatzetzou, S.; Liaptsi, E.; Lazaridou, I. Z.; Kokkotis, C.; Makri, E.; Ioannidou, M.; Aggelousis, N.; Vadikolias, K. Unexplored Roles of Erythrocytes in Atherothrombotic Stroke. Neurology international, 2023,v15(1), 124–139.
4. Papadopoulos, C.; Panopoulou, M.; Anagnostopoulos, K.; Tentes, I. Immune and Metabolic Interactions of Human Erythrocytes: A Molecular Perspective. Endocr. Metab. Immune Disord. Drug Targets 2021, 21, 843–853.
5. Papadopoulos, C.; Anagnostopoulos, K.; Tentes, I. Erythrocytes contribute to the immunometabolic cross-talk. Immunometabolism 2021, 3, e210015.
6. Papadopoulos, C.; Tentes, I.; Anagnostopoulos, K. Lipotoxicity Disrupts Erythrocyte Function: A Perspective. Cardiovasc. Hematol. Disord. Drug Targets 2021, 21, 91–94.
7. Papadopoulos, C.; Tentes, I.; Anagnostopoulos, K. Molecular Interactions between Erythrocytes and the Endocrine System. Maedica 2021, 16, 489.
8. Papadopoulos, C. Erythrocyte Glucotoxicity Results in Vascular Inflammation. Endocr. Metab. Immune Disord. Drug Targets 2022, 22, 901–903.
9. Papadopoulos, C. Immunosuppressive Function of Intratumor Red Blood Cells: An Immune-Metabolic Perspective. Curr. Cancer Rev. 2022, 18, 224–226.
10. Papadopoulos, C.; Anagnostopoulos, K.; Tentes, I. Red Blood Cell Dysfunction in Non-Alcoholic Fatty Liver Disease: Marker and Mediator of Molecular Mechanisms., Maedica, 2020; 15(4): 513–516
11. Papadopoulos, C.; Anagnostopoulos, K.; Tentes, I. An Immunometabolic Pathway for Hyperglycemia?-Commentary on: Packed Red Blood Cells Inhibit T-Cell Activation via ROS-Dependent Signaling Pathways. Immunometabolism, 2021, 3(4):e210027
12. Papadopoulos, C.; Tentes, I.; Papazoglou, D.; Anagnostopoulos, K. Lysophospholipid Metabolism and Signalling in Non-Alcoholic Fatty Liver Disease. Folia medica, 2020, 64(1), 7–12
13. Papadopoulos, C.; Spourita, E.; Tentes, I.; Steiropoulos, P.; Anagnostopoulos, K. Red Blood Cell Malfunction in COVID-19: Molecular Mechanisms and Therapeutic Targets. Viral Immunology, 2022, 35(10):649-652

Conference Presentations

1. Papadopoulos C. Immunometabolic pathways in non-alcoholic steatohepatitis. 7th Conference of Medical Research and Education, 2023, Alexandroupolis, Greece.
2. Papadopoulos C, Spourita E, Tentes I, Anagnostopoulos K. Reduced erythrocyte CD47 levels in NASH patients. 21st Hellenic Hepatology Conference, 2023, Ioannina, Greece. 
3. Papadopoulos C, Mimidis K, Spourita E, Anagnostopoulos K. Activation of the P2X7 receptor of red blood cells triggers MCP1 release. Modulatory effect of cholesterol depletion. 71st Conference of the Hellenic Society for Biochemistry and Molecular Biology, 2021, Athens
4. Papadopoulos C, Tentes I, Anagnostopoulos K. Cytokine profile of the interaction between erythrocyte from patients with Non- Alcoholic Fatty Liver Disease and macrophage cell line RAW 264.7: The role of lipid signaling. Hellenic Pharmacology Conference, 2020, Αlexandroupolis